Breaking News
The Economist Who Predicted 2008 Explains China's Endgame
Charlie Kirk SNAPS at Anti White Masked ANTIFA
Episode 488: THE FAUCI FIRESTORM
Discussion with Glen DiesenTop Tech News
Shade-Resistant Solar Cells Retain 97% Efficiency After 2,000 Hours of Testing
20 Ancient Engineering SECRETS
Stonehenge Was Reanalyzed by AI -- And the Findings Are Hard to Explain
After Years Of Delays, Aptera Is Finally Preparing To Build Customer Cars
'When you kill it, it doesn't die': the jellyfish that has cracked the secret of immorta
Archer Aviation debuts Halo autonomous VTOL, Thunder's commercial twin
US Telecoms Slide On Starlink Mobile Threat; Bernstein Sees It As A "Jab, But No Knockout Yet**
Betavolt unveils revolutionary coin-size battery with nickel-63 nuclear isotope...
China claims it has built a 'nuclear drone' that can stay airborne forever
Canada just solved two giant infrastructure problems at exactly the same time.
Experimental cancer drug that targets common genetic fault can shrink tumours...
An experimental cancer drug that targets a common genetic fault has been shown to shrink tumours by up to 67 per cent in just six weeks.
Scientists tested their newly developed anti-cancer drug AMG 510 on four patients, two of whom saw their tumours shrink. It did not work for the others.
In studies on mice, the treatment helped to shrink, and in some cases eradicate, the growing tumours.
The daily pill works by turning 'off' the KRAS gene. Mutated forms of the genes are permanently trapped 'on', causing cancerous cells to multiply.
This abnormal activity fuels the development of up to 50 per cent of lung cancers, as well as some pancreatic and bowel cancers.
The pharmaceutical company described their findings as a 'milestone' for patients with cancer KRAS-mutant cancers.
The research was led by by pharmaceutical company Amgen Research, based in Thousand Oaks, California.
The findings, published in Nature, are the first to report the effects of inhibiting KRAS with a drug.